These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 18829557)

  • 1. Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104.
    Liu SC; Ahn GO; Kioi M; Dorie MJ; Patterson AV; Brown JM
    Cancer Res; 2008 Oct; 68(19):7995-8003. PubMed ID: 18829557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
    Hay MP; Anderson RF; Ferry DM; Wilson WR; Denny WA
    J Med Chem; 2003 Dec; 46(25):5533-45. PubMed ID: 14640560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo.
    Theys J; Pennington O; Dubois L; Anlezark G; Vaughan T; Mengesha A; Landuyt W; Anné J; Burke PJ; Dûrre P; Wouters BG; Minton NP; Lambin P
    Br J Cancer; 2006 Nov; 95(9):1212-9. PubMed ID: 17024128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
    Mowday AM; Ashoorzadeh A; Williams EM; Copp JN; Silva S; Bull MR; Abbattista MR; Anderson RF; Flanagan JU; Guise CP; Ackerley DF; Smaill JB; Patterson AV
    Biochem Pharmacol; 2016 Sep; 116():176-87. PubMed ID: 27453434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapeutic tumour targeting using clostridial spores.
    Minton NP; Mauchline ML; Lemmon MJ; Brehm JK; Fox M; Michael NP; Giaccia A; Brown JM
    FEMS Microbiol Rev; 1995 Oct; 17(3):357-64. PubMed ID: 7576773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spores of Clostridium engineered for clinical efficacy and safety cause regression and cure of tumors in vivo.
    Heap JT; Theys J; Ehsaan M; Kubiak AM; Dubois L; Paesmans K; Van Mellaert L; Knox R; Kuehne SA; Lambin P; Minton NP
    Oncotarget; 2014 Apr; 5(7):1761-9. PubMed ID: 24732092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mammalianized synthetic nitroreductase gene for high-level expression.
    Grohmann M; Paulmann N; Fleischhauer S; Vowinckel J; Priller J; Walther DJ
    BMC Cancer; 2009 Aug; 9():301. PubMed ID: 19712451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virus-directed enzyme prodrug therapy using CB1954.
    Grove JI; Searle PF; Weedon SJ; Green NK; McNeish IA; Kerr DJ
    Anticancer Drug Des; 1999 Dec; 14(6):461-72. PubMed ID: 10834268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis.
    Liu SC; Minton NP; Giaccia AJ; Brown JM
    Gene Ther; 2002 Feb; 9(4):291-6. PubMed ID: 11896468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase.
    Weedon SJ; Green NK; McNeish IA; Gilligan MG; Mautner V; Wrighton CJ; Mountain A; Young LS; Kerr DJ; Searle PF
    Int J Cancer; 2000 Jun; 86(6):848-54. PubMed ID: 10842200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
    Atwell GJ; Yang S; Pruijn FB; Pullen SM; Hogg A; Patterson AV; Wilson WR; Denny WA
    J Med Chem; 2007 Mar; 50(6):1197-212. PubMed ID: 17326614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase.
    Hay MP; Atwell GJ; Wilson WR; Pullen SM; Denny WA
    J Med Chem; 2003 Jun; 46(12):2456-66. PubMed ID: 12773049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations.
    Jaberipour M; Vass SO; Guise CP; Grove JI; Knox RJ; Hu L; Hyde EI; Searle PF
    Biochem Pharmacol; 2010 Jan; 79(2):102-11. PubMed ID: 19665450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment.
    Lemmon MJ; van Zijl P; Fox ME; Mauchline ML; Giaccia AJ; Minton NP; Brown JM
    Gene Ther; 1997 Aug; 4(8):791-6. PubMed ID: 9338007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice.
    Gu Y; Guise CP; Patel K; Abbattista MR; Li J; Sun X; Atwell GJ; Boyd M; Patterson AV; Wilson WR
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):543-55. PubMed ID: 20473609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia.
    Fox ME; Lemmon MJ; Mauchline ML; Davis TO; Giaccia AJ; Minton NP; Brown JM
    Gene Ther; 1996 Feb; 3(2):173-8. PubMed ID: 8867865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dinitrobenzamide mustard prodrugs, PR-104A and SN27686, for use in a novel MNDEPT cancer prodrug therapy approach.
    Ball P; Thompson E; Anderson S; Gwenin V; Ashoorzadeh A; Smaill J; Gwenin C
    Biosci Rep; 2023 Apr; 43(4):. PubMed ID: 37067816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the abilities of diverse nitroaromatic prodrug metabolites to exit a model Gram negative vector for bacterial-directed enzyme-prodrug therapy.
    Chan-Hyams JVE; Copp JN; Smaill JB; Patterson AV; Ackerley DF
    Biochem Pharmacol; 2018 Dec; 158():192-200. PubMed ID: 30352235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954.
    Djeha AH; Hulme A; Dexter MT; Mountain A; Young LS; Searle PF; Kerr DJ; Wrighton CJ
    Cancer Gene Ther; 2000 May; 7(5):721-31. PubMed ID: 10830719
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Mowday AM; Copp JN; Syddall SP; Dubois LJ; Wang J; Lieuwes NG; Biemans R; Ashoorzadeh A; Abbattista MR; Williams EM; Guise CP; Lambin P; Ackerley DF; Smaill JB; Theys J; Patterson AV
    Theranostics; 2020; 10(23):10548-10562. PubMed ID: 32929365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.